查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1721417

生物製藥市場機會、成長動力、產業趨勢分析及 2025 - 2034 年預測

Biopharmaceutical Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034
出版日期: | 出版商: Global Market Insights Inc. | 英文 145 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2024 年全球生物製藥市場價值為 4,225 億美元，預計到 2034 年將以 8.2% 的複合年成長率成長至 9,215 億美元，這得益於慢性病和罕見患者病率的上升，以及對生物製劑和精準治療的需求不斷增加。隨著全球醫療保健系統轉向個人化治療，生物製藥因其在分子層面上針對疾病機制的能力而獲得發展動力。生物技術的快速進步——尤其是基因編輯、細胞療法和下一代蛋白質工程等領域——為治療曾經被認為無法治癒的疾病開闢了新的可能性。

生物製藥市場 - IMG1

生活方式相關疾病的負擔日益加重、人口老化以及腫瘤學、神經病學和免疫學領域未滿足的臨床需求繼續推動全球需求。政府和私人投資者正在向研發投入大量資金，推動創新管道並加快藥物開發時間表。監管機構也採取了加快核准途徑，以便更快地將救命的治療方法推向市場，進一步促進成長。隨著生物相似藥和數位療法進入主流醫療保健，各地區複雜治療的可負擔性和可近性正在提高，重塑了全球生物製藥領域的競爭格局。

市場範圍
起始年份 2024
預測年份 2025-2034
起始值 4225億美元
預測值 9215億美元
複合年成長率 8.2%

細胞和基因療法等生物技術的突破正在改變腫瘤學、免疫學和神經病學的治療模式。生物相似藥正變得越來越普及，提高了可負擔性並擴大了獲得救命生物製劑的機會。高成本生物製劑的生物相似藥日益增多，有助於解決藥物可近性問題，尤其是在發展中市場。 mRNA技術的創新也正在重新定義疾病預防和治療方案，為該領域的快速擴張做出重大貢獻。在藥物研發和臨床試驗中採用人工智慧和數位平台正在簡化操作並提高藥物研發的成功率。

按產品類型分類，單株抗體領域在 2023 年創造了 2,250 億美元的收入，這得益於其在治療癌症、自體免疫疾病和傳染病等複雜健康狀況方面的高效性和特異性。該領域強勁的市場表現歸功於持續的研究和開發、生物藥物核准的增加以及治療應用的擴大。抗體工程的不斷進步和多種適應症的臨床突破正在推動全球對單株抗體療法的需求。

在應用方面，腫瘤學領域在 2024 年佔據了 30.9% 的顯著市場。隨著治療變得更加有針對性和有效性，生物製藥在癌症治療中的應用正在迅速擴大。全球癌症負擔日益加重，推動了對提供分子精度和免疫系統調節的生物療法的需求。阻止腫瘤進展和干擾癌細胞訊號傳導的創新方法正在重塑癌症治療模式，進一步推動該領域的成長。

2023 年，美國生物製藥市場產值達 1,552 億美元。其領先地位得益於強力的監管政策、先進的研究基礎設施以及生物技術公司、製藥巨頭和學術機構之間的合作。該國對基因編輯、生物製劑和個人化醫療的關注鞏固了其全球地位。強勁的研發投入和先進治療平台的快速採用繼續推動該地區的市場擴張。

全球生物製藥市場的主要活躍參與者包括默克、強生、輝瑞、葛蘭素史克、山德士、武田製藥、拜耳、安進、賽諾菲、羅氏、諾華、阿斯特捷利康、諾和諾德、艾伯維、百健、禮來和百時美施貴寶。這些公司透過擴大產品線、收購生物技術新創公司和建立策略全球合作夥伴關係來增強其市場影響力。對研發、治療多樣化以及臨床試驗和藥物輸送最佳化的數位化整合進行大量投資仍然是重中之重。與研究機構和醫療保健提供者的合作正在加速監管部門的核准，並確保創新療法更快上市。

目錄

第1章：方法論與範圍

第2章：執行摘要

第3章：行業洞察

  • 產業生態系統分析
  • 產業衝擊力
    • 成長動力
      • 慢性病盛行率上升
      • 生物技術和基因治療的進展
      • 生物相似藥的採用日益增多
    • 產業陷阱與挑戰
      • 生產和開發成本高
      • 監管和核准的複雜性
  • 成長潛力分析
  • 監管格局
  • 波特的分析
  • PESTEL分析

第4章：競爭格局

  • 介紹
  • 公司矩陣分析
  • 公司市佔率分析
  • 主要市場參與者的競爭分析
  • 競爭定位矩陣
  • 策略儀表板

第5章：市場估計與預測：依產品類型，2021-2034

  • 主要趨勢
  • 單株抗體
  • 疫苗
  • 荷爾蒙
  • 促紅血球生成素
  • 胰島素
  • 生長和凝血因子
  • 干擾素
  • 其他產品類型

第6章：市場估計與預測：按應用，2021-2034

  • 主要趨勢
  • 腫瘤學
  • 血液疾病
  • 傳染病
  • 代謝性疾病
  • 心血管疾病
  • 神經系統疾病
  • 免疫學
  • 其他應用

第7章：市場估計與預測：依藥物類型，2021-2034

  • 主要趨勢
  • 專有（品牌）
  • 生物相似藥

第8章：市場估計與預測：按製造類型，2021-2034 年

  • 主要趨勢
  • 外包
  • 內部

第9章：市場估計與預測：按管理路線，2021-2034

  • 主要趨勢
  • 注射劑
  • 口服
  • 其他給藥途徑

第 10 章：市場估計與預測：按處方類型，2021-2034 年

  • 主要趨勢
  • 處方藥
  • 非處方藥

第 11 章：市場估計與預測：按配銷通路，2021-2034 年

  • 主要趨勢
  • 醫院藥房
  • 藥局和零售藥局
  • 網路藥局

第 12 章：市場估計與預測：按地區，2021 年至 2034 年

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 荷蘭
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第13章：公司簡介

  • AbbVie
  • Amgen
  • AstraZeneca
  • Bayer
  • Biogen
  • Bristol-Myers Squibb
  • Eli Lilly
  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck
  • Novartis
  • Novo Nordisk
  • Pfizer
  • Sanofi
  • Sandoz
  • Takeda Pharmaceutical
簡介目錄
Product Code: 13479

The Global Biopharmaceutical Market was valued at USD 422.5 billion in 2024 and is estimated to grow at a CAGR of 8.2% to reach USD 921.5 billion by 2034, driven by the rising prevalence of chronic illnesses and rare diseases, along with increasing demand for biologics and precision therapies. As healthcare systems worldwide shift toward personalized treatment, biopharmaceuticals are gaining momentum for their ability to target disease mechanisms at the molecular level. The rapid advancements in biotechnology-especially in areas like gene editing, cell therapies, and next-gen protein engineering-are unlocking new possibilities for treating conditions once considered incurable.

Biopharmaceutical Market - IMG1

The growing burden of lifestyle-related diseases, aging populations, and unmet clinical needs in oncology, neurology, and immunology continue to propel global demand. Governments and private investors are pouring significant capital into R&D, boosting innovation pipelines and accelerating drug development timelines. Regulatory agencies are also adopting expedited approval pathways to bring life-saving treatments to market faster, further encouraging growth. As biosimilars and digital therapeutics enter mainstream healthcare, affordability and access to complex treatments are improving across various regions, reshaping the competitive landscape of the global biopharmaceutical space.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$422.5 Billion
Forecast Value$921.5 Billion
CAGR8.2%

Breakthroughs in biotechnology, such as cell and gene therapies, are transforming the treatment landscape for conditions in oncology, immunology, and neurology. Biosimilars are becoming more widely available, improving affordability and expanding access to life-saving biologics. The growing availability of biosimilar versions of high-cost biologics is helping address drug accessibility issues, especially in developing markets. Innovations in mRNA technology are also redefining disease prevention and treatment protocols, contributing significantly to the sector's rapid expansion. The adoption of AI and digital platforms in drug discovery and clinical trials is streamlining operations and enhancing success rates across drug pipelines.

By product type, the monoclonal antibodies segment generated USD 225 billion in 2023, owing to their high efficacy and specificity in managing complex health conditions like cancer, autoimmune diseases, and infectious ailments. The strong market performance of this segment is attributed to continuous research and development, increasing approvals for biologic drugs, and broadening therapeutic applications. Ongoing advancements in antibody engineering and clinical breakthroughs across multiple indications are fueling the demand for monoclonal antibody therapies worldwide.

On the application front, the oncology segment held a significant market share of 30.9% in 2024. The use of biopharmaceuticals in cancer care is expanding rapidly as treatments become more targeted and effective. The growing global cancer burden is pushing the demand for biologic-based therapies that offer molecular precision and immune system modulation. Innovative approaches that block tumor progression and interfere with cancer cell signaling are reshaping the cancer treatment paradigm, further driving growth in this segment.

The U.S. Biopharmaceutical Market generated USD 155.2 billion in 2023. Its leadership is supported by robust regulatory policies, cutting-edge research infrastructure, and collaborations among biotech firms, pharmaceutical giants, and academic institutions. The country's focus on gene editing, biologics, and personalized medicine has strengthened its global position. Strong R&D investments and rapid adoption of advanced therapy platforms continue to fuel market expansion across the region.

Key players active in the Global Biopharmaceutical Market include Merck, Johnson & Johnson, Pfizer, GlaxoSmithKline, Sandoz, Takeda Pharmaceutical, Bayer, Amgen, Sanofi, F. Hoffmann-La Roche, Novartis, AstraZeneca, Novo Nordisk, AbbVie, Biogen, Eli Lilly, and Bristol-Myers Squibb. These companies are enhancing their market presence by expanding product pipelines, acquiring biotech startups, and forming strategic global partnerships. Heavy investments in R&D, therapeutic diversification, and digital integration for clinical trials and drug delivery optimization remain top priorities. Collaborations with research institutions and healthcare providers are accelerating regulatory approvals and ensuring faster time-to-market for innovative therapies.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates and calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 3600 synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising prevalence of chronic diseases
      • 3.2.1.2 Advancements in biotechnology and gene therapy
      • 3.2.1.3 Growing adoption of biosimilars
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 High production and development costs
      • 3.2.2.2 Regulatory and approval complexities
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Porter's analysis
  • 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Company market share analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2021-2034 ($ Mn)

  • 5.1 Key trends
  • 5.2 Monoclonal antibody
  • 5.3 Vaccine
  • 5.4 Hormone
  • 5.5 Erythropoietin
  • 5.6 Insulin
  • 5.7 Growth and coagulation factor
  • 5.8 Interferon
  • 5.9 Other product types

Chapter 6 Market Estimates and Forecast, By Application, 2021-2034 ($ Mn)

  • 6.1 Key trends
  • 6.2 Oncology
  • 6.3 Blood disorders
  • 6.4 Infectious diseases
  • 6.5 Metabolic diseases
  • 6.6 Cardiovascular diseases
  • 6.7 Neurological diseases
  • 6.8 Immunology
  • 6.9 Other applications

Chapter 7 Market Estimates and Forecast, By Drug Type, 2021-2034 ($ Mn)

  • 7.1 Key trends
  • 7.2 Proprietary (Branded)
  • 7.3 Biosimilars

Chapter 8 Market Estimates and Forecast, By Manufacturing Type, 2021-2034 ($ Mn)

  • 8.1 Key trends
  • 8.2 Outsource
  • 8.3 In-house

Chapter 9 Market Estimates and Forecast, By Route of Administration, 2021-2034 ($ Mn)

  • 9.1 Key trends
  • 9.2 Injectables
  • 9.3 Oral
  • 9.4 Other routes of administration

Chapter 10 Market Estimates and Forecast, By Prescription Type, 2021-2034 ($ Mn)

  • 10.1 Key trends
  • 10.2 Prescription medicines
  • 10.3 Over the counter (OTC) medicines

Chapter 11 Market Estimates and Forecast, By Distribution channel, 2021-2034 ($ Mn)

  • 11.1 Key trends
  • 11.2 Hospital pharmacies
  • 11.3 Drug stores and retail pharmacies
  • 11.4 Online pharmacies

Chapter 12 Market Estimates and Forecast, By Region, 2021-2034 ($ Mn)

  • 12.1 Key trends
  • 12.2 North America
    • 12.2.1 U.S.
    • 12.2.2 Canada
  • 12.3 Europe
    • 12.3.1 Germany
    • 12.3.2 UK
    • 12.3.3 France
    • 12.3.4 Spain
    • 12.3.5 Italy
    • 12.3.6 Netherlands
  • 12.4 Asia Pacific
    • 12.4.1 China
    • 12.4.2 Japan
    • 12.4.3 India
    • 12.4.4 Australia
    • 12.4.5 South Korea
  • 12.5 Latin America
    • 12.5.1 Brazil
    • 12.5.2 Mexico
    • 12.5.3 Argentina
  • 12.6 Middle East and Africa
    • 12.6.1 South Africa
    • 12.6.2 Saudi Arabia
    • 12.6.3 UAE

Chapter 13 Company Profiles

  • 13.1 AbbVie
  • 13.2 Amgen
  • 13.3 AstraZeneca
  • 13.4 Bayer
  • 13.5 Biogen
  • 13.6 Bristol-Myers Squibb
  • 13.7 Eli Lilly
  • 13.8 F. Hoffmann-La Roche
  • 13.9 GlaxoSmithKline
  • 13.10 Johnson & Johnson
  • 13.11 Merck
  • 13.12 Novartis
  • 13.13 Novo Nordisk
  • 13.14 Pfizer
  • 13.15 Sanofi
  • 13.16 Sandoz
  • 13.17 Takeda Pharmaceutical